Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics

Cancer

Volumn 80, Issue 11, 1997, Pages 2084-2090

  Bartlett, David L ^a   Ma, Grace ^a   Alexander, H Richard ^a   Libutti, Steven K ^a   Fraker, Douglas L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hyperthermia; In transit; Limb perfusion; Medical oncology; Melanoma; Melphalan; Metastases; Tumor necrosis factor

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; DACARBAZINE; DACTINOMYCIN; GAMMA INTERFERON; MELPHALAN; THIOTEPA; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT SYNDROME; FEMALE; FEVER; HEART ARRHYTHMIA; HUMAN; HYPERTHERMIC THERAPY; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEG BLOOD FLOW; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; REPERFUSION; SKIN NECROSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARM; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LEG; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; PERFUSION; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030667332     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971201)80:11<2084::AID-CNCR7>3.0.CO;2-X     Document Type: Article

References (27)

1. Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-32.
2. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969; 129:305-8.
3. Alexander HR, Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 1996; 12:416-28.
4. Guchelaar HJ, Hoekstra HJ, de Vries EGE, Uges DRA, Oosterhuis JW, Koops HS. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumors of the extremities. Br J Cancer 1992;65:898-902.
5. Fletcher WS, Pommier RF, Woltering EA, Mueller CR, Ash O, Small KA. Pharmacokinetics and results of dose escalation in cisplatin hyperthermic isolation limb perfusion. Ann Surg Oncol 1994;1(3):236-43.
6. Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, Hart AAM. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion using melphalan. Surgery 1994;115:39-45.
7. Fraker DL, Alexander HR, Bartlett DL, Rosenberg SA. A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF) and interferon-gamma (IFN): an initial report [abstract]. Soc Surg Oncol 1996;49:6.
8. Coit DG, Bajorin DF, Menendez-Botet C, Shiu MH, Sclafani L, Niedzwiecki D, Ray C. A phase I trial of hyperthermic isolation limb perfusion (HILP) using cisplatin (CDDP) for metastatic melanoma [meeting abstract]. Proc Am Soc Clin Oncol 1991;10:1028.
9. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992;16:227-33.
10. Krementz ET, Carter RD, Sutherland CM, Muchmore JH, Ryan RF, Creech O. Regional chemotherapy for melanoma. A 35-year experience. Ann Surg 1994;220:520-35.
11. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
12. Pennica DG, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984;312:724-9.
13. Asher AL, Mulé JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-74.
14. Palladino MA, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, et al. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 1987;138:4023-32.
15. Havell EA, Fiers W, North RJ. The antitumor function of tumor necrosis factor (TNF). J Exp Med 1988;167:1067-85.
16. Fraker DL, Alexander HR, Pass HI. Biologic therapy with TNF: systemic administration and isolation-perfusion. In: DeVita V, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: J.B. Lippincott Co., 1995:329-45.
17. Lienard D, Lejeune F, Ewalenko I. In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992;16:234-40.
18. Cumberlin R, DeMoss E, Lassus M, Friedman M. Isolation perfusion for malignant melanoma of the extremity: a review. J Clin Oncol 1985;3:1022-31.
19. Schraffordt-Koops H, Kroon BBR, Lejeune FJ. Isolated regional perfusion in the treatment of local recurrence, satellites and in-transit metastases of extremity melanoma. In: Rumke P, editor. Therapy of advanced melanoma. Basel: Karger, 1990:67-78.
20. Barker WC, Andrich MP, Alexander HR, Fraker DL. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 1995;22:1242-8.
21. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a TNF dose escalation study. J Clin Oncol 1996;14:479-89.
22. Skene AL, Bulman AS, Williams TR, Thomas JM, Westbury G. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990;77:765-7.
23. Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, van Dongen JA. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993;71:2990-4.
24. Klaase JM, Kroon BBR, van Geel BN, Eggermont AMM, Franklin HR, Hart GAM. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994; 167:618-20.
25. Klop JM, Vrouenrets BC, van Geel BN, Eggermont AM, Klaase JM, Nieweg OE, et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 1996;182:467-72.
26. Libutti SK, Alexander HR, Bartlett DL, Rosenberg SA, Fraker DL. Patterns of local failure in extremity melanoma after a complete response to isolated limb perfusion with melphalan with or without tumor necrosis factor. Proc Am Soc Clin Oncol 1996;15:552.
27. Lejeune FJ. A randomized trial on prophylactic isolation perfusion for stage I high risk (i.e. 1.5 mm thickness) malignant melanoma of the limbs: an interim report. Melanoma Res 1993;3(Suppl):95.